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Abstract 
After Taxotere fails, treatment options for metastatic prostate cancer are limited. The three 
drugs with FDA approval in this setting, Jevtana, Provenge and Zytiga, are associated with 
median survivals of less than 2 years. In part, the impact on survival is the result of low 
response rates, indicating a significant proportion of patients exhibiting de novo resistance 
to these agents. An alternate approach is to let treatment selection be governed by gene 
expression profiling so that the treatment is tailored to the specific patient. Here, we report 
a case of metastatic prostate cancer with a dramatic response to treatment selected based 
on molecular profiling. This patient had failed LHRH agonist, bicalutamide, Taxotere, and 
doxorubicin. Molecular profiling showed overexpression of the androgen receptor and he 
had a dramatic response of measurable disease to second-line hormonal therapy with 
ketoconazole, estrogen and Leukine. 
 
Introduction 
Between 20 and 30,000 men die each year from prostate cancer. For a vast majority 
of these men, death comes after progression through androgen withdrawal and 
Taxotere chemotherapy. Before the arrival of Jevtana, Zytiga and Provenge, the median 
survival after Taxotere was roughly 12 months [1]. These three new drugs each have  
Case Rep Oncol 2012;5:154–158 
DOI: 10.1159/000338077 
Published online: 
March 29, 2012 
© 2012 S. Karger AG, Basel 
ISSN 1662–6575 
www.karger.com/cro 
 
 
 
155 
published median survivals of less than 18 months [2–4]. Studies have shown that 
androgen receptor overexpression is present in many prostate cancers after Taxotere 
[5]. This was the rationale for the development of Zytiga and now MDV3100. After the 
use of FDA-approved drugs, there is a fairly long list of drugs where phase II results 
suggest possible clinical utility and this includes 5-flurouracil, doxorubicin, 
platinum-based drugs, methotrexate, and etoposide. However, there has been no 
reliable way to identify which of these drugs might have the greatest chance at success. 
For most of these drugs, the genes that influence response are known and gene 
expression profiling offers promise as a means to select agents with the greatest chance 
of success. In this case report, we present a patient who had failed LHRH agonist, pure 
antiandrogen, Taxotere and doxorubicin. Molecular profiling showed androgen 
receptor overexpression and treatment with ketoconazole, estrogen and Leukine was 
associated with a dramatic response in measurable disease. 
Case Report 
This patient was diagnosed with prostate cancer in August of 2000. In September of 2000, he had a 
radical prostatectomy done at Johns Hopkins. The Gleason grade was 4 + 3 = 7 with vascular invasion. 
The specimen showed bilateral capsular penetration, but the seminal vesicles and margins were 
negative. His pathological stage was pT3a N0 Mx. His first post-operative PSA was 0.4 ng/ml in 
December of 2000. At that time, his PSA doubling time was approximately 2 weeks. CT scan done in 
March 2001 showed a 2.8 × 1.8 cm left external iliac lymph node. He was given neoadjuvant Zoladex 
and Casodex followed by external beam radiation between May and July of 2001.  
He relapsed by January 2002 with a PSA doubling time of one month. Again, CT scan showed an 
enlarged left iliac lymph node. By September of 2002, this node had increased to 3.6 × 2.5 cm. He was 
then placed on a clinical protocol that combined Taxotere and doxorubicin with hormonal therapy. He 
had a dramatic PSA response with his PSA dropping from 5 to 0.1 ng/ml. The CT scan showed the 
lymph node had decreased to 1.3 × 1.2 cm. 
Again, off hormonal therapy, his PSA resumed its one-month doubling time. This was correlated 
with regrowth of a single lymph node. At this point, the lymph node was surgically removed during 
the winter of 2005. It was pathologically positive for prostate cancer. At this point, he entered a short 
remission with an undetectable PSA and negative staging studies until he recurred in July of 2006 
with an increasing PSA and a 1.4 × 1.7 cm lymph node again in his left pelvis. This time the enlarging 
node was treated with radiation. This resulted in a PSA that dropped to 0.04 ng/ml. By May of 2008, 
his PSA again started to increase and a left perirectal node was found at a previously radiated site. At 
this point, intermittent hormonal therapy was recommended. 
By March 2010, he had recurred with a PSA doubling time of 3 months while on hormonal therapy. 
This was associated with lower abdominal pain and a perirectal mass. A biopsy of the mass showed no 
PSA expression. In May of 2010, the mass was incompletely removed surgically and showed poorly 
differentiated carcinoma. He was placed on a clinical trial testing MDV3100, where he was 
randomized to the placebo arm. 
By March of 2011, he had a 2.2 × 1.7 × 6.1 cm mass at the bifurcation of the aorta. In the left 
hemipelvis, he had a 3.5 × 2.8 cm mass. While he had a PSA of only 0.45 ng/ml, CT scan showed a 
large pelvic mass. His bone scan was negative. The surgical specimen from May 2010 was analyzed 
with Target NowTM (Caris Life Sciences, Phoenix, Ariz., USA). Target Now analysis showed 
androgen receptor overexpression at the protein and RNA level. The staining intensity by 
immunohistochemistry was 3+ in 80% of cells and AR at the mRNA level was overexpressed 2.9-fold 
over control tissue as determined by gene expression. Estrogen and progesterone receptor levels 
were also tested but they were found to be negative. Based on the molecular profiling results in March 
11, 2011, he was started on a combination of ketoconazole, estradiol and Leukine. Ketoconazole was 
initiated at 200 mg every 8 h and escalated to patient tolerance, which was 600 mg every 8 h. Vivelle 
dot transdermal estradiol patches 0.1 mg/day were used. These patches are designed to be replaced  
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every 3.5 days. We had him place 4 new patches on each day and these were replaced after 3 days. 
Thus, at any one time, the patient had 12 patches on. This gave a serum estradiol that ranged between 
180–360 pg/ml. Leukine was started at 250 mcg per day, but escalated to 500 mcg per day based on 
patient tolerance. Testosterone levels remained undetectable at less than 15 ng/dl. By August 2011, 
CT scans showed dramatic resolution of one pelvic mass, partial resolution of the second lesion and a 
PSA nadir of 0.06 ng/ml (fig. 1). Throughout his prostate cancer history, his bone scans have 
remained negative.  
Discussion 
Androgen withdrawal is standard initial treatment for metastatic prostate cancer. 
However, most men with advanced disease eventually develop castration resistance. 
Taxotere is the standard initial chemotherapy after failure of androgen withdrawal and 
is associated with median survivals between 16 and 19 months. Cabazitaxel is the 
standard second-line chemotherapy agent and it is associated with median survivals of 
15 months as compared to just over 12 months for the control group. 
Interestingly, in patients who have failed Taxotere, tumor specimens often show 
overexpression of the androgen receptor. Recent studies demonstrate the so-called 
‘castration-resistant’ tumors are still dependent on androgen receptor signaling. 
Various molecular mechanisms (e.g., androgen receptor gene amplification, 
overexpression, or mutations, enhanced AR signal transduction) have been reported in 
castration-resistant prostate cancers [6]. These molecular mechanisms allow the 
androgen receptor to be activated at castrate levels of testosterone. This has been 
confirmed in a series of laboratory experiments where prostate cancer cell lines have 
been developed that grow well at 1/100 to 1/1,000 the normal testosterone 
concentration. Overexpression of the androgen receptor is one of the more common 
mechanisms involved in this adaptation to low androgen levels. Androgen receptor 
tyrosine phosphorylation has also been shown to facilitate androgen receptor function 
at low testosterone levels. These findings have led to a search for better means of 
reducing serum testosterone levels or blocking the androgen receptor. 
Abiraterone, a 17 α-hydroxylase/C17,20 lyase (CYP17A1) receptor antagonist, is the 
first drug approved to address this problem. Abiraterone is very effective at inhibiting 
synthesis of testosterone as serum levels of this hormone become undetectable. This 
drug was FDA-approved for post-Taxotere patients based on a survival extension of 3.9 
months. 
At the time this patient started second-line treatment in March 2011, the FDA had 
not yet approved abiraterone. For this reason, we chose to use ketoconazole, an 
older drug reported to decrease androgen synthesis. In addition to inhibiting 
17 α-hydroxylase/C17,20 lyase, ketoconazole also inhibits a wide range of other 
microsomal enzymes and hence, lacks the specificity of abiraterone. This lack of 
specificity on the part of ketoconazole makes it a much difficult drug to use clinically 
unlike abiraterone [2]. 
We elected to add Leukine to the treatment program based on reports of synergy 
between ketoconazole and Leukine. Investigators at University of California San 
Francisco reported a 75% response to this combination in patients who had failed 
androgen withdrawal [7]. Finally, we added transdermal estradiol because estradiol is  
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also reported to decrease serum testosterone. This strategy proved successful and 
serum testosterone levels have remained undetectable during treatment [8]. 
Conclusions 
In summary, this patient had failed extensive treatment with hormonal therapy as 
well as treatment with Taxotere/doxorubicin. While he was clinically hormone 
refractory, his cancer overexpressed androgen receptor and he has had radiologic 
response of his cancer after 5 months on second-line hormonal therapy. Molecular 
profiling was successful in predicting response to second-line hormonal therapy in this 
heavily pretreated patient. 
Disclosure Statement 
Caris Life Sciences employs Gargi Basu and Brian Wright. Charles E. Myers is funded to participate 
in a clinical trial funded by Caris Life Sciences to evaluate the role of molecular profiling in the 
management of advanced prostate cancer patients. 
 
 
 
 
Fig. 1. The patient had two metastatic lesions at the start of treatment. In each image, the metastatic 
lesion location is indicated by the white arrow. a and b show one metastasis before and after 
treatment, respectively. c and d show the second lesion before and after treatment, respectively. 
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